Completed first-patient enrollment (FPI) in an NIH-led IV BCV clinical trial for progressive multifocal leukoencephalopathy
SymBio Pharmaceuticals Limited and the National Institute of Neurological Disorders and Stroke (NINDS) within the U.S. National Institutes of Health (NIH)
NIH Clinical Center (Bethesda, Maryland), intravenous brincidofovir (IV BCV), and patients with progressive multifocal leukoencephalopathy (PML)
No amount disclosed. There is no impact on the earnings forecast for the fiscal year ending December 2026.
This matter will have no impact on the earnings forecast for the fiscal year ending December 2026.
Related procedures
Investigator-initiated clinical trial
U.S. National Institutes of Health (NIH) and National Institute of Neurological Disorders and Stroke (NINDS)
The company will advance development for PML and multiple sclerosis together with NIH/NINDS and expand its business in the field of neurodegenerative diseases.
| Item | Details |
|---|---|
| Event name | Completed first-patient enrollment (FPI) in an NIH-led IV BCV clinical trial for progressive multifocal leukoencephalopathy |
| Subject Entity | SymBio Pharmaceuticals Limited and the National Institute of Neurological Disorders and Stroke (NINDS) within the U.S. National Institutes of Health (NIH) |
| Target Locations / Products | NIH Clinical Center (Bethesda, Maryland), intravenous brincidofovir (IV BCV), and patients with progressive multifocal leukoencephalopathy (PML) |
| Amount of Impact on Business Performance | No amount disclosed. There is no impact on the earnings forecast for the fiscal year ending December 2026. |
| Impact on Earnings Forecast | This matter will have no impact on the earnings forecast for the fiscal year ending December 2026. |
| Type of litigation or proceeding | Investigator-initiated clinical trial |
| Court or authority | U.S. National Institutes of Health (NIH) and National Institute of Neurological Disorders and Stroke (NINDS) |
| Outlook | The company will advance development for PML and multiple sclerosis together with NIH/NINDS and expand its business in the field of neurodegenerative diseases. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that the trial is being conducted to evaluate the efficacy and safety of IV BCV for PML and build clinical knowledge.